The association between Wilms tumor 1 (WT1) expression, genetic abnormalities, and homozygous single nucleotide polymorphism (SNP) in the WT1 gene was evaluated in 252 patients with acute myelogenous leukemia. WT1 expression correlated with prognostic genetic abnormalities. Homozygous WT1 SNP rs16754 was associated with lower expression of WT1. However, WT1 expression had no prognostic effect in any cytogenetic group or SNP status. Background: The prognostic effect of Wilms tumor 1 (WT1) expression at the diagnosis of acute myelogenous leukemia (AML) has been controversial. The aim of the present study was to determine the correlations of WT1 expression at the diagnosis of AML with established prognostic alterations. Patients and Methods: We analyzed diagnostic bone marrow samples from 252 patients. WT1 expression, single nucleotide polymorphism (SNP) in the WT1 gene (rs16754), and Fms-like tyrosine kinase receptor-3 internal tandem duplication (FLT3-ITD) mutation were analyzed for all patients. The nucleophosmin 1 (NPM1) mutation and CCAAT/enhancer-binding protein-a (CEBPA) double mutation were analyzed for cytogenetically normal (CN)-AML. The KIT mutation was analyzed for core-binding factor AML. Results: Within the cytogenetically favorable prognosis group, WT1 expression in AML with inv(16) or t(15;17) was significantly greater than that in AML with t(8;21). In cases with CN-AML, FLT3-ITD and NPM1 mutations both correlated with greater expression of WT1, and the CEBPA double mutation was related to lower WT1 Clinical Lymphoma, Myeloma & Leukemia November 2018 -e469 expression. The existence of both FLT3-ITD and NPM1 mutations showed synergistically greater expression of WT1 in CN-AML. SNP in the WT1 gene (rs16754) was significantly associated with lower expression of WT1. The WT1 levels were not prognostic factors in the total cohort or any cytogenetic group or stratified by SNP status. Conclusion: Because WT1 expression has correlated with known prognostic factors, the prognostic effect of WT1 levels could be misunderstood depending on the distribution of the collaborative mutations in each cohort. We have concluded that the prognostic significance of WT1 at the diagnosis of AML is weak compared with the other established prognostic factors.
Introduction
The Wilms tumor 1 (WT1) gene, located in chromosome 11p13, encodes a DNA-binding protein with 4 zinc finger domains.
1,2 The WT1 protein is a unique transcription factor that can activate or repress target promoters depending on the cellular cofactors it binds to. 3 More than 70% of patients with acute myelogenous leukemia (AML) will have overexpression of WT1 at diagnosis. [4] [5] [6] [7] Whether the WT1 transcript levels at diagnosis are predictive of the outcomes of AML patients is controversial. [8] [9] [10] [11] [12] [13] [14] [15] However, the cytogenetic categories and certain molecular mutations have been proved to be risk factors in AML. 16 Patients with core-binding factor (CBF) AML or AML with t(15;17) have had better overall survival. Fmslike tyrosine kinase receptor-3 internal tandem duplication (FLT3-ITD), nucleophosmin 1 (NPM1), and CCAAT/enhancer-binding protein-a (CEBPA) double mutations have also been established as prognostic risk factors in cytogenetically normal (CN)-AML. Risk stratification using these cytogenetic categories and molecular abnormalities has already been integrated into clinical practice. 16 The relationship between WT1 expression and each cytogenetic category has not been fully determined. In the present study, we analyzed the data from 252 AML patients and determined the prognostic significance of the WT1 levels at diagnosis in each cytogenetic category.
Patients and Methods

Patients
The Hokkaido Leukemia Net consists of 15 hospitals covering the entire Hokkaido prefecture in Japan. Bone marrow samples from AML patients were collected from throughout Hokkaido and studied for relevant molecular markers at the central laboratory of Hokkaido University Hospital. Patients with AML diagnosed from October 2007 to May 2017 were enrolled in the present study. WT1 expression and FLT3-ITD mutation were analyzed using the diagnostic bone marrow samples from all patients. The present study was conducted in compliance with the ethical principles of the Declaration of Helsinki. The institutional review board of each participating hospital approved the present study. All the patients provided written informed consent after sufficient explanation by an investigator or subinvestigator before samples were taken.
Molecular Analysis
FLT3-ITD, NPM1, CEBPA, and KIT mutations were analyzed using a genome DNA template. The relevant region of FLT3 was amplified by polymerase chain reaction (PCR), and gel electrophoresis was run to verify the presence of the ITD band. After cytogenetic analysis, the NPM1 mutation and CEBPA double mutation were analyzed for CN-AML. NPM1 exon 12 and the entire CEBPA were directly sequenced. The KIT mutation was analyzed for CBF-AML. KIT exons 8, 9, 11, and 17 were directly sequenced. The presence of the TP53 mutation was not determined in the present study.
WT1 Expression Analysis
RNA was extracted from diagnostic bone marrow using a QIAamp RNA Blood Mini Kit (Qiagen, Valencia, CA). Complimentary DNA (cDNA) was synthesized from 1 mg of extracted RNA using a Transcriptor First Strand cDNA Synthesis Kit (Roche Diagnostics, Mannheim, Germany). The primer and probe sequences used for real-time quantitative reverse transcriptase PCR were as follows:
WT1: WT1-forward, GGGTACGAGAGCGA-TAACCACA; WT1-reverse, TCTCAGATGCCGACCGTACAA; WT1-minor groove binder (MGB), CAGAATACA-CACGCACGGT. As a copy number control, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was amplified using GAPDHforward, GAAGGTGAAGGTCGGAGT; GAPDH-reverse, GAA-GATGGTGATGGGATTTC, and GAPDH-MGB, AAGCTTCCCGTTCTCA. Real-time quantitative reverse transcriptase PCRs were performed using the real-time PCR system Step One Plus (Applied Biosystems, Foster City, CA). For quantification of WT1 transcripts in patient samples, the samples were always amplified simultaneously with a standard dilution of K562 cDNA. K562 is a human erythroleukemic cell line that consistently expresses WT1. 17 The WT1 transcript levels in the samples were determined by reference to the corresponding transcript levels of K562 cells. WT1 single nucleotide polymorphism (SNP; rs16754) was analyzed using genome DNA. The primers for PCR at WT1 gene exon 7 were as follows: forward, TACTCCAGTGCT-CACTCTCCC; reverse, GGCAAACATGGTTCAAGAGCT. The PCR product was digested by HpyCH4IV (New England Biolabs, Ipswich, MA). Because the SNP broke the HpyCH4IV recognition site from "ACGT" to "GCGT," the SNP status can be identified using gel electrophoresis of the digested PCR product (Supplemental Figure 1 ; available in the online version).
Statistical Analysis
Differences between the groups of data of continuous variables were analyzed using the Mann-Whitney U test. Differences between 2 groups of categorical data were analyzed using Fisher's exact test. A Cox proportional hazard model was used to investigate the survival time. Overall survival was defined as the time from the diagnosis to death or the last follow-up examination. P < .05 was considered to indicate statistical significance. All statistical analyses were performed with EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan). 18 
Results
WT1 Expression and Cytogenetic Abnormalities
A total of 252 AML patients were enrolled in the present study. The patients were divided into 6 groups according to the cytogenetic abnormalities, including t(8;21), inv(16), t(15;17), CN, poor cytogenetics, and other. Poor cytogenetics was defined as a complex karyotype (! 3 clonal chromosomal abnormalities), monosomal karyotype, or karyotypes containing À5, 5qÀ, À7, 7qÀ, 11q23 non-t(9;11), inv(3), t(3;3), t(6;9), and t(9;22) according to the National Comprehensive Cancer Network (NCCN) guidelines. 16 The patient characteristics are listed in We then divided the patients into 3 risk groups according to the validated cytogenetics and molecular abnormalities in the NCCN guidelines, except for TP53 mutation. This classification showed a clear prognostic difference in our cohort ( Figure 1A ). In contrast, no significant difference was found in overall survival between the patients in the WT1 high expression group and low expression group, although the low WT1 group tended to have a slightly poorer prognosis (P ¼ .393; Figure 1B ). We then analyzed WT1 expression in each cytogenetic risk group (Figure 2 ). WT1 levels varied in the cytogenetic categories, with particularly high levels in the inv (16) Figure 2 ; available in the online version).
WT1 Expression in CN-AML
For the cases with CN-AML, positivity of FLT3-ITD and NPM1 mutations correlated with greater expression of WT1 and CEBPA double mutations correlated with lower WT1 expression (P < .001, P < .001, and P ¼ .023, respectively; Figure 3 ). Combined analysis of FLT3-ITD and NPM1 mutations showed synergistically high WT1 expression in patients with both mutations (Supplemental Figure 3A ; available in the online version). As previously shown and classified in the NCCN guidelines, 16 FLT3-ITD þ CN-AML patients had a poor prognosis but FLT3-ITD À and NPM1 mutation þ patients had a better prognosis (Supplemental Figure 3B ; available in the online). FLT3-ITD positivity was also high in the t(15;17) group. However, the positivity of FLT3-ITD correlated weakly with high WT1 expression in the t(15;17) group. Also, the poor prognostic effect of FLT3-ITD was not significant in the t(15;17) group (Supplemental Figure 4 ; available in the online version).
Prognostic Significance of WT1 Expression in Each Cytogenetic Risk Group
Because WT1 expression correlated with both a poor prognostic factor (FLT3-ITD in CN-AML) and better prognostic factors [inv (16) , t(15;17), NPM1, and CEBPA double mutation in Figure 5B ). However, no prognostic effect when stratified by SNP status ( Figure 5C ).
Discussion
WT1 expression will be detected in most AML patients. 5, 13, 19 It was hypothesized that high WT1 expression originated from a high leukemic cell population; however, a direct correlation between the blast percentage or CD34 positivity and WT1 expression was not confirmed. 20 In our study, WT1 expression at the diagnosis of AML varied by a > 4 log range. High WT1 expression could not have originated only from the large number of leukemic blasts in the specimen because the blast percentage at diagnosis varied from 20% to 100%. Thus, investigators speculated that the levels of WT1 expression would reflect the biological differences in the AML in each patient. Many studies were performed to determine the clinical effect of WT1 expression for survival or disease progression. In patients with myelodysplastic syndrome, greater WT1 expression consistently correlated with earlier disease progression to AML and a poor prognosis. 21, 22 However, the prognostic significance of WT1 in patients with AML at diagnosis is still controversial. Several studies have reported inconsistent findings concerning the prognostic effect of WT1 expression in AML patients (Table 2) . [8] [9] [10] [11] [12] [13] [14] Some reports showed a greater prognostic effect with greater WT1 expression, 8, 11, 13, 24, 25 and other reports showed a greater prognostic effect of lower WT1 expression. 9, 10, 12, 15, 26 The prognostic effect of WT1 was evaluated using the entire AML cohort in most of these reports. However, as we, and some previous studies, have shown, WT1 expression can be correlated with certain cytogenetic abnormalities. Previous studies showed that high WT1 expression correlated with AML with inv(16), NPM1 mutation, 27 and 11q23 abnormality 28 and that low WT1 expression correlated with AML with t(8;21). 28 Another group showed that low WT1 expression at diagnosis predicted for poor outcomes for patients with AML with t(8;21). 9 That group also showed that a KIT mutation correlated with low WT1 expression. 9 A KIT mutation in patients with CBF leukemia is known as a poor prognostic factor, especially CBF leukemia with t(8;21). 16 In our series, patients with the KIT mutation in t(8;21) tended to have lower WT1 expression and a poorer outcome; however, the difference was not statistically significant (Supplemental Figure 2 ; available in the online version). The greater allogeneic hematopoietic stem cell transplantation (allo-HSCT) ratio in KIT-mutated t(8;21) than in KITenonmutated t(8;21) groups (44.4% vs. 28.0%) could have improved the poor outcomes of the KIT-mutated group in our cohort. In our study, patients with inv(16) and t(15;17) had greater WT1 expression than that in patients with t(8;21). FLT3-ITD or NPM1 mutation in CN-AML was independently associated with high WT1 expression, and the CEBPA double mutation correlated with lower WT1 expression. It is important to know the correlations of WT1 levels with the background cytogenetic abnormalities, because the sensitivity of WT1 as a minimal residual disease marker might be different in AML with high WT1 expression and AML with low WT1 expression. A biologic explanation for the prognostic effect of the WT1 transcript level at the diagnosis of AML remains unclear. Many apparently contradictory functions have been described for the WT1 gene, which has been considered to be an oncogene or a tumor suppressor gene. However, evidence has been emerging that the WT1 protein can exhibit both properties under different cellular conditions. 29, 30 These complex functions of WT1 were cited to explain the contradictory results. Because of the inconsistent results for the prognostic effect, WT1 has not been integrated into the AML risk stratification. 16, 31 Our cohort is the second-largest cohort in this field of research and includes unbiased patients from the Hokkaido region. The main limitation of the present study was the retrospective study design, such that patients with a poor risk group classification could have been treated intensively, resulting in improved outcomes. However, NCCN risk stratification was still effective, even in our heterogeneously treated cohort in which 32.9% of the patients underwent allo-HSCT. The relatively large sample size enabled us to determine the WT1 levels in each cytogenetic category. After dividing the patients into cytogenetic abnormality groups, the WT1 levels still did not have any prognostic effect in each group. We also analyzed the cohort excluding those patients who had undergone allo-HSCT. However, the prognostic significance of WT1 expression at diagnosis was not verified (data not shown). A SNP in the WT1 gene (rs16754) was initially reported as a positive prognostic factor for AML patients. 23, 26 However, after a report showed the inconsistent prognostic effect of the SNP (Supplemental Table 1 ; available in the online version). [32] [33] [34] [35] [36] [37] [38] [39] This SNP was disproportionately distributed across ethnic groups, with greater prevalence in Asian and Hispanic patients. 26, 35, 37, 38 Our cohort had a high prevalence of the SNP, reflecting Japanese ethnicity. The SNP correlated with lower WT1 levels in AML; however, SNP status did not correlate with survival in our cohort.
Conclusion
In the present study, we found that the WT1 levels at the diagnosis of AML were significantly associated with certain cytogenetics, collaborative leukemic mutations, or the existence of SNP rs16754. However, in any cytogenetic category, WT1 expression did not show a clear prognostic significance. Thus, the prognostic significance of WT1 at the diagnosis of AML is weak compared with that of other established prognostic factors. Correlations between WT1 expression and cytogenetic abnormalities should be confirmed in other series to determine whether our findings can be reproduced.
Clinical Practice Points
WT1 expression in AML correlated with prognostic genetic abnormalities. Homozygous WT1 SNP rs16754 was associated with lower expression of WT1. WT1 expression did not have a prognostic effect when stratified by genetic category or SNP status.
